Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation design, formulation, and manufacture of poorly soluble molecules, today announced that it has entered into a collaboration with KC Pharmaceuticals for the development of five over-the-counter (OTC) sterile ophthalmic drop medicines.
KC Pharmaceuticals will leverage Ascendia’s formulation development and analytical testing capabilities to develop these new products. KC Pharmaceuticals will leverage its manufacturing and distribution expertise to commercialize the products.
(Source: Ascendia Pharmaceuticals)